Iovance Biotherapeutics Inc (IOVA) Shares Bought by American International Group Inc.

American International Group Inc. lifted its stake in Iovance Biotherapeutics Inc (NASDAQ:IOVA) by 27.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,703 shares of the biotechnology company’s stock after acquiring an additional 15,190 shares during the period. American International Group Inc. owned approximately 0.06% of Iovance Biotherapeutics worth $617,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in IOVA. BlackRock Inc. lifted its holdings in shares of Iovance Biotherapeutics by 32.0% during the fourth quarter. BlackRock Inc. now owns 8,780,191 shares of the biotechnology company’s stock valued at $77,706,000 after acquiring an additional 2,126,213 shares during the period. Perceptive Advisors LLC lifted its holdings in shares of Iovance Biotherapeutics by 24.6% during the third quarter. Perceptive Advisors LLC now owns 7,290,199 shares of the biotechnology company’s stock valued at $82,014,000 after acquiring an additional 1,437,997 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Iovance Biotherapeutics by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,048,782 shares of the biotechnology company’s stock valued at $45,550,000 after acquiring an additional 302,649 shares during the period. Vanguard Group Inc lifted its holdings in shares of Iovance Biotherapeutics by 8.1% during the third quarter. Vanguard Group Inc now owns 4,048,782 shares of the biotechnology company’s stock valued at $45,550,000 after acquiring an additional 302,649 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in shares of Iovance Biotherapeutics by 24.3% during the fourth quarter. Victory Capital Management Inc. now owns 3,021,927 shares of the biotechnology company’s stock valued at $26,744,000 after acquiring an additional 591,270 shares during the period. Institutional investors and hedge funds own 96.33% of the company’s stock.

A number of research analysts have issued reports on the company. Oppenheimer reissued a “buy” rating on shares of Iovance Biotherapeutics in a report on Tuesday, March 19th. ValuEngine raised Iovance Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 4th. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price target on shares of Iovance Biotherapeutics in a report on Tuesday, April 2nd. BidaskClub raised Iovance Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, February 4th. Finally, Zacks Investment Research raised Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Friday, January 4th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $22.86.

Shares of IOVA traded up $0.08 on Friday, hitting $11.10. The company’s stock had a trading volume of 662,342 shares, compared to its average volume of 1,023,552. Iovance Biotherapeutics Inc has a fifty-two week low of $7.26 and a fifty-two week high of $18.25. The firm has a market capitalization of $1.36 billion, a PE ratio of -8.74 and a beta of 1.91.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.27). As a group, research analysts anticipate that Iovance Biotherapeutics Inc will post -1.22 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/iovance-biotherapeutics-inc-iova-stake-boosted-by-american-international-group-inc.html.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

See Also: Is it better to buy a fund with a higher or lower NAV?

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.